Crystalline forms of an NK-1 antagonist

A method of making a liquid dosage form comprising mixing a crystalline micronized free-base form of the compound 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propenamide and one or more liquid pharmaceutical excipients, wherein the compound has an X-ray powder diffraction pattern comprising one or more characteristic peaks in terms of 2θ at 4.5°±0.2°;

• 8.4°±0.2°;
• 11.5°±0.2°;
• 13.1°±0.2°;
• 13.9°±0.2°;
• 14.8°±0.2°;
• 16.7°±0.2°;
• 17.4°±0.2°;
• 17.7°±0.2°;
• 19.5°±0.2°;
• 21.2°±0.2°;
• 21.6°±0.2°;
• or 21.8°±0.2°.